Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease

Kidney International

Volumn 87, Issue 1, 2015, Pages 210-216

  Meijers, Björn ^a,b   Poesen, Ruben ^b   Claes, Kathleen ^a,b   Dietrich, Ruth ^c   Bammens, Bert ^a,b   Sprangers, Ben ^a,b   Naesens, Maarten ^a,b   Storr, Markus ^c   Kuypers, Dirk ^a,b   Evenepoel, Pieter ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Gambro Dialysatoren GmbH   (Germany)

Author keywords

Cardiovascular events; chronic kidney disease; urokinase

Indexed keywords

UROKINASE RECEPTOR; BIOLOGICAL MARKER; PLAUR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; MIDDLE AGED;

ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RENAL INSUFFICIENCY, CHRONIC;

EID: 84920277849     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.197     Document Type: Article

References (33)

1. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
2. Wei C, Moller CC, Altintas MM et al. Modification of kidney barrier function by The urokinase receptor. Nat Med 2008; 14: 55-63.
3. Nebuloni M, Zawada L, Ferri A et al. HIV-1 infected lymphoid organs upregulate expression and release of The cleaved form of uPAR that modulates chemotaxis and virus expression. PLoS One 2013; 8: e70606.
4. Outinen TK, Tervo L, Makela S et al. Plasma levels of soluble urokinase-type plasminogen activator receptor associate with The clinical severity of acute Puumala hantavirus infection. PLoS One 2013; 8: e71335.
5. Rabna P, Andersen A, Wejse C et al. Utility of The plasma level of suPAR in monitoring risk of mortality during TB treatment. PLoS One 2012; 7: e43933.
6. Ostrowski SR, Ullum H, Goka BQ et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005; 191: 1331-1341.
7. Slot O, Brunner N, Locht H et al. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999; 58: 488-492.
8. Lonnkvist MH, Theodorsson E, Holst M et al. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scand J Gastroenterol 2011; 46: 420-427.
9. Backes Y, van der Sluijs KF, Mackie DP et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 2012; 38: 1418-1428.
10. Lyngbaek S, Marott JL, Sehestedt T et al. Cardiovascular risk prediction in The general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol 2013; 167: 2904-2911.
11. Persson M, Engstrom G, Bjorkbacka H et al. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from The Malmo Diet and Cancer Study. Atherosclerosis 2012; 220: 502-505.
12. Lyngbaek S, Marott JL, Moller DV et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol 2012; 110: 1756-1763.
13. Lyngbaek S, Andersson C, Marott JL et al. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain. Clin Chem 2013; 59: 1621-1629.
14. Koch A, Voigt S, Kruschinski C et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during The first week of treatment in The intensive care unit and predicts mortality in critically ill patients. Crit Care 2011; 15: R63.
15. Wei C, El HS, Li J et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 952-960.
16. Meijers B, Maas RJ, Sprangers B et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 2014; 85: 636-640.
17. Bock ME, Price HE, Gallon L et al. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 2013; 8: 1304-1311.
18. Franco Palacios CR, Lieske JC, Wadei HM et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 2013; 96: 394-399.
19. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and The risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
20. Foley R, Parfrey P, Sarnak M. The clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119.
21. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from The american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108: 2154-2169.
22. Maas RJ, Deegens JK, Wetzels JF. Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 2013; 28: 1041-1048.
23. Naesens M, Meijers B, Sprangers B. suPAR and FSGS: The gap between bench and bedside. Transplantation 2013; 96: 368-369.
24. Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007; 357: 1316-1325.
25. Stinghen AE, Bucharles S, Riella MC et al. Immune mechanisms involved in cardiovascular complications of chronic kidney disease. Blood Purif 2010; 29: 114-120.
26. Carrero JJ, Ortiz A, Qureshi AR et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 110-118.
27. Liabeuf S, Barreto DV, Barreto FC et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with The mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010; 25: 2596-2602.
28. Almroth G, Lonn J, Uhlin F et al. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients? Scand J Immunol 2013; 78: 285-290.
29. Chavakis T, Willuweit AK, Lupu F et al. Release of soluble urokinase receptor from vascular cells. Thromb Haemost 2001; 86: 686-693.
30. Edsfeldt A, Nitulescu M, Grufman H et al. Soluble urokinase plasminogen activator receptor is associated with inflammation in The vulnerable human atherosclerotic plaque. Stroke 2012; 43: 3305-3312.
31. Pawlak K, Mysliwiec M, Pawlak D. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thromb Res 2008; 122: 328-335.
32. Meijers BK, Claes K, Bammens B et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182-1189.
33. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.